| human | Q5 |
| P10070 | IRIS UNIPG author ID | 49138 |
| P496 | ORCID iD | 0000-0003-2064-6071 |
| P11597 | Padua Research Archive author ID | 19025 |
| P1053 | ResearcherID | AAV-9491-2020 |
| P1153 | Scopus author ID | 7005605212 |
| P69 | educated at | University of Padua | Q193510 |
| P108 | employer | University of Padua | Q193510 |
| P734 | family name | Pengo | Q30089730 |
| Pengo | Q30089730 | ||
| Pengo | Q30089730 | ||
| P735 | given name | Vittorio | Q3834677 |
| Vittorio | Q3834677 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q61928680 | A Comparison of Lupus Anticoagulant–Positive Patients With Clinical Picture of Antiphospholipid Syndrome and Those Without |
| Q50775104 | A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy. |
| Q35879764 | A Randomized Trial of Pharmacogenetic Warfarin Dosing in Naïve Patients with Non-Valvular Atrial Fibrillation |
| Q34150640 | A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty. |
| Q38075995 | A combination therapy protocol of plasmapheresis, intravenous immunoglobulins and betamethasone to treat anti-Ro/La-related congenital atrioventricular block. A case series and review of the literature |
| Q61063479 | A combination therapy to treat second-degree anti-Ro/La-related congenital heart block. A strategy to avoid stable third-degree heart block? |
| Q53294913 | A comparison between six- and four-week intervals in surveillance of oral anticoagulant treatment. |
| Q47810463 | A contribution to the debate on the laboratory criteria that define the antiphospholipid syndrome |
| Q43796154 | A simple scheme to initiate oral anticoagulant treatment in outpatients with nonrheumatic atrial fibrillation |
| Q47730463 | A two-step coagulation test to identify antibeta-glycoprotein I lupus anticoagulants |
| Q37832035 | APS--controversies in diagnosis and management, critical overview of current guidelines. |
| Q52927023 | Accuracy of a portable prothrombin time monitor (Coagucheck) in patients on chronic oral anticoagulant therapy: a prospective multicenter study. |
| Q95317674 | Additional Laboratory Tests to Improve on the Diagnosis of Antiphospholipid Syndrome |
| Q38876334 | Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review |
| Q59075500 | An approach to differential diagnosis of antiphospholipid antibody syndrome and related conditions |
| Q91182896 | An in vitro model to mimic the thrombotic occlusion of small vessels in catastrophic antiphospholipid syndrome (CAPS) |
| Q83789628 | An unusual acute coronary syndrome: undisclosed disease hidden under a confounding clinical presentation |
| Q71018619 | Anti beta 2-glycoprotein I antibodies in a patient with catastrophic antiphospholipid syndrome |
| Q51731982 | Anti-beta(2)-glycoprotein I ELISA assay: the influence of different antigen preparations. |
| Q81831090 | Anti-beta2-glycoprotein I antibody testing in the laboratory diagnosis of antiphospholipid syndrome |
| Q87279480 | Antibodies to Domain 4/5 (Dm4/5) of β2-Glycoprotein 1 (β2GP1) in different antiphospholipid (aPL) antibody profiles |
| Q84212281 | Antibodies to Domain I of β(2)Glycoprotein I are in close relation to patients risk categories in Antiphospholipid Syndrome (APS) |
| Q46712223 | Antibodies to oxidized LDL/beta2-glycoprotein I in antiphospholipid syndrome patients with venous and arterial thromboembolism |
| Q80213989 | Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity |
| Q81873167 | Antibody profiles for the diagnosis of antiphospholipid syndrome |
| Q96301503 | Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs |
| Q61649492 | Antiphosphatidylserine/prothrombin antibodies in primary antiphospholipid syndrome |
| Q83186154 | Antiphosphlipid syndrome classification criteria: comments to the Letter of Jakub Swadzba and Jacek Musial |
| Q47588734 | Antiphospholipid antibody ELISAs: survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-beta2-Glycoprotein I activity |
| Q38280840 | Antiphospholipid syndrome and the heart: a case series and literature review |
| Q86646346 | Antiphospholipid syndrome: antibodies to Domain 1 of β2-glycoprotein 1 correctly classify patients at risk |
| Q83954306 | Antiphospholipid syndrome: critical analysis of the diagnostic path |
| Q44719836 | Antiphospholipid syndrome: interpretation of laboratory data |
| Q37842673 | Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment. |
| Q81479229 | Antithrombotic strategies for atrial fibrillation: on the threshold of changes? No |
| Q46679463 | Apolipoprotein E (APOE) and warfarin dosing in an Italian population |
| Q40389777 | Application of wavelet analysis to the phonocardiographic signal of mechanical heart valve closing sounds. |
| Q33391969 | Argatroban in the management of heparin-induced thrombocytopenia. |
| Q84611000 | Aspirin and recurrent venous thromboembolism in patients with symptomatic atherosclerosis: retrospective cohort study |
| Q38734321 | Assessing the relative potency of (S)- and (R)-warfarin with a new PK-PD model, in relation to VKORC1 genotypes. |
| Q74709473 | Association of the G20210A mutation in the factor II gene with systemic embolism in nonvalvular atrial fibrillation |
| Q68951306 | Beta-thromboglobulin (beta-TG) and platelet factor 4 (PF4) release by adenosine diphosphate (ADP) contact with native whole blood |
| Q51777848 | Bileaflet mechanical heart valve closing sounds: in vitro classification by phonocardiographic analysis. |
| Q72024105 | Binding of autoimmune cardiolipin-reactive antibodies to heparin: a mechanism of thrombosis? |
| Q84377198 | Biological variation of INR in stable patients on long-term anticoagulation with warfarin |
| Q103026976 | Bleeding and thrombotic complications during treatment with direct oral anticoagulants or vitamin K antagonists in venous thromboembolic patients included in the prospective, observational START2-register |
| Q71264573 | Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy |
| Q85473529 | Cancer as a risk factor for stroke in atrial fibrillation patients receiving long-term oral anticoagulant therapy |
| Q37740293 | Cancer prevention and vitamin K antagonists: an overview |
| Q36303250 | Cardiovascular risk factors are major determinants of thrombotic risk in patients with the lupus anticoagulant |
| Q91144736 | Catastrophic antiphospholipid syndrome: Lessons from 14 cases successfully treated in a single center. A narrative report |
| Q33844273 | Chemical synthesis and characterization of wild-type and biotinylated N-terminal domain 1-64 of beta2-glycoprotein I. |
| Q27014135 | Chronic thromboembolic pulmonary hypertension |
| Q84227566 | Circulating β2 glycoprotein I-IgG anti-β2 glycoprotein I immunocomplexes in patients with definite antiphospholipid syndrome |
| Q53889534 | Clinical conundrums in antithrombotic therapy management: A Delphi Consensus panel. |
| Q38081946 | Clinical management of rivaroxaban-treated patients |
| Q38209471 | Clinical relevance of β₂-glycoprotein-I plasma levels in antiphospholipid syndrome (APS). |
| Q97679754 | Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry |
| Q51584315 | Comparative classification of thrombotic formations on bileaflet mechanical heart valves by phonographic analysis. |
| Q73515207 | Comparison between routine laboratory prothrombin time measurements and fingerstick determinations using a near-patient testing device (Pro-Time) |
| Q92304261 | Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository |
| Q45383876 | Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile. |
| Q40662456 | Contemporary Burden of Atrial Fibrillation and Associated Mortality in Northeastern Italy |
| Q38065593 | Correct laboratory approach to APS diagnosis and monitoring. |
| Q37990564 | Current anticoagulant safety |
| Q34576728 | D-dimer testing to determine the duration of anticoagulation therapy |
| Q91131658 | D-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study |
| Q42655195 | Data from a multidisciplinary poll of 178 expert physicians on the usage of non-vitamin K Oral Anticoagulants in patients with atrial fibrillation and venous thromboembolism |
| Q45915405 | Deep venous thrombosis after surgery for inflammatory bowel disease: is standard dose low molecular weight heparin prophylaxis enough? |
| Q33269104 | Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM). |
| Q95835691 | Design and rationale of a randomized, placebo-controlled trial on the efficacy and safety of sulodexide for extended treatment in elderly patients after a first venous thromboembolism |
| Q39042314 | Detection of lupus anticoagulant in the era of direct oral anticoagulants |
| Q43993039 | Development of artificial neural network-based algorithms for the classification of bileaflet mechanical heart valve sounds |
| Q74706941 | Diabetic ketosis activates lymphomonocyte-inducible nitric oxide synthase |
| Q90202151 | Diagnostics and treatment of thrombotic antiphospholipid syndrome (APS): A personal perspective |
| Q44765414 | Difference in mortality after hip fracture is associated with postdischarge prescription of antithrombotic prophylaxis: a case-control study |
| Q42778526 | Dosing of clopidogrel and aspirin in acute coronary syndromes |
| Q33425705 | Dyspnoea in a young woman: the opposite of every truth is just as true |
| Q92048496 | EULAR recommendations for the management of antiphospholipid syndrome in adults |
| Q53827335 | Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study. |
| Q46704454 | Effectiveness and safety of a management protocol to correct over-anticoagulation with oral vitamin K: a retrospective study of 1,043 cases. |
| Q77178177 | Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation |
| Q28218634 | Efficacy and safety of nadroparin in the treatment of pregnant women with antiphospholipid syndrome: a prospective cohort study |
| Q38159868 | Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. |
| Q37847175 | Emerging anticoagulants |
| Q83389363 | Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies |
| Q83826092 | False-negative or false-positive: laboratory diagnosis of lupus anticoagulant at the time of commencement of anticoagulant: a rebuttal |
| Q33361525 | Features associated with epilepsy in the antiphospholipid syndrome |
| Q33153262 | From acute pulmonary embolism to chronic thromboembolic pulmonary hypertension |
| Q37950724 | High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: 'PROS' and 'CONS'. |
| Q84430794 | Higher levels of plasma matrix metalloproteinase-2 are associated with a significantly increased risk of arterial thrombosis in patients with the antiphospholipid syndrome |
| Q72695618 | IPO-V2: a prospective, multicenter, randomized, comparative clinical investigation of the effects of sulodexide in preventing cardiovascular accidents in the first year after acute myocardial infarction |
| Q95424170 | ISTH guidelines on lupus anticoagulant testing |
| Q56378292 | Impact of Chronic Renal Failure on Ischemic and Bleeding Events at 1 Year in Patients With Acute Coronary Syndrome (from the Multicenter START ANTIPLATELET Registry) |
| Q37065161 | Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis |
| Q50619255 | Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. |
| Q41747738 | Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant |
| Q34323100 | Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. |
| Q44259188 | Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. |
| Q81743030 | Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification |
| Q103049134 | Insight into the hypercoagulable state of high-risk thrombotic APS patients: Contribution of aβ2GPI and aPS/PT antibodies |
| Q34283606 | Interpretation of laboratory data and need for reference laboratories. |
| Q38123237 | Investigational anticoagulants for hematological conditions: a new generation of therapies. |
| Q83385117 | Is the analysis over the time domain or over the frequency domain significant for the detection of bileaflet mechanical heart valve dysfunction? |
| Q80577073 | Knowledges about herbal products among subjects on warfarin therapy and patient-physician relationship: a pilot study |
| Q61649548 | Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome |
| Q81232007 | Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy |
| Q86826367 | Laboratory tests during direct oral anticoagulant treatment? Yes |
| Q39608521 | Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome |
| Q45154416 | Long-term warfarin use to prevent both stroke and dementia in subjects with atrial fibrillation? |
| Q33392850 | Low molecular weight heparin (parnaparin) for cardioembolic events prevention in patients with atrial fibrillation undergoing elective electrical cardioversion: a prospective cohort study |
| Q50275300 | Lower versus standard intensity oral anticoagulant therapy (OAT) in elderly warfarin-experienced patients with non-valvular atrial fibrillation |
| Q45868808 | Lupus anticoagulant (LA) testing: performance of clinical laboratories assessed by a national survey using lyophilized affinity-purified immunoglobulin with LA activity |
| Q93351189 | Lupus anticoagulant identifies two distinct groups of patients with different antibody patterns |
| Q54688696 | Major bleeding in patients undergoing PCI and triple or dual antithrombotic therapy: a parallel-cohort study. |
| Q56381361 | Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry |
| Q36685166 | Management of oral anticoagulant treatment in patients with venous thromboembolism |
| Q80114226 | Management of patients on long-term oral anticoagulant therapy undergoing elective surgery: survey of the clinical practice in the Italian anticoagulation clinics |
| Q37880656 | Management of special conditions in patients on vitamin K antagonists |
| Q38345740 | Managing dentoalveolar surgical procedures in patients taking new oral anticoagulants |
| Q56334923 | Mechanical prosthetic heart valves: Quality of anticoagulation and thromboembolic risk. The observational multicenter PLECTRUM study |
| Q84024781 | Mild inflammation may switch on again atrial fibrillation after successful electrical cardioversion |
| Q38389058 | Minimizing the risk of hemorrhagic stroke during anticoagulant therapy for atrial fibrillation. |
| Q80188593 | Monitoring oral anticoagulants: new strategies for an emerging problem |
| Q84564300 | More on: laboratory investigation of lupus anticoagulants: mixing studies are sometimes required |
| Q40623535 | Mortality associated to atrial fibrillation still on the rise: United States, 1999 to 2014. |
| Q35870011 | New trends in anticoagulant therapy |
| Q36283533 | New trends in anticoagulant treatments. |
| Q35806482 | Oral anticoagulant therapy in patients with atrial fibrillation |
| Q43604229 | PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. |
| Q38280730 | Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. |
| Q89999916 | Patients with isolated pulmonary embolism in comparison to those with deep venous thrombosis. Differences in characteristics and clinical evolution |
| Q45820728 | Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function |
| Q86529972 | Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results: a reply to a rebuttal |
| Q80874123 | Plasma exchange for the management of the catastrophic antiphospholipid syndrome: importance of the type of fluid replacement |
| Q36731865 | Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A report of 9 cases and a review of the literature. |
| Q41046279 | Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics |
| Q61649484 | Platelet and endothelial activation in catastrophic and quiescent antiphospholipid syndrome |
| Q38229559 | Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A 'state-of-the-art' paper |
| Q50059140 | Point of Care Testing (POCT) to assess drug concentration in patients treated with non-vitamin K antagonist oral anticoagulants (NOACs). |
| Q79540823 | Positive stress test in a patient with patent coronary artery grafts |
| Q37479088 | Prasugrel for the treatment of patients with acute coronary syndrome |
| Q85075314 | Prescription of vitamin K inhibitors in low-risk patients with atrial fibrillation |
| Q61928679 | Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with Lupus Anticoagulant (LA) |
| Q90857980 | Prevalence of antiphospholipid (aPL) antibodies among patients with chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis |
| Q57300453 | Prevalence of heart diseases in patients with pulmonary embolism with and without peripheral venous thrombosis |
| Q37554153 | Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention |
| Q91704326 | Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs |
| Q72762755 | Purification of anticardiolipin and lupus anticoagulant activities by using cardiolipin immobilized on agarose beads |
| Q84985096 | Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA) |
| Q72607749 | Radioiodinated fibrinogen in the evaluation of patients with osteosarcoma |
| Q37286644 | Recovery from catastrophic antiphospholipid syndrome by a plasma exchange procedure: report of four cases and review of the literature. |
| Q41619784 | Relationship between antiphosphatidylserine/prothrombin and conventional antiphospholipid antibodies in primary antiphospholipid syndrome |
| Q84580495 | Right ventricular dysfunction in patients diagnosed with pulmonary embolism |
| Q90200352 | Risk factors for intracranial hemorrhage during vitamin K antagonist therapy in patients with nonvalvular atrial fibrillation: A case-control study |
| Q84302565 | Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study |
| Q34145656 | Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review |
| Q48695086 | Risk stratification and outcomes in hemodynamically stable patients with acute pulmonary embolism: a prospective, multicentre, cohort study with three months of follow-up |
| Q61649509 | Risk-based secondary prevention of obstetric antiphospholipid syndrome |
| Q33986110 | Risks factors for highly unstable response to oral anticoagulation: a case-control study |
| Q90007363 | Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome |
| Q80021996 | Sex and anticoagulation in patients with idiopathic venous thromboembolism |
| Q80014448 | Should patients with mitral stenosis and atrial fibrillation receive combined antithrombotic therapy? |
| Q53203652 | Sixth meeting of the European Forum on antiphospholipid antibodies. How to improve the understanding of the antiphospholipid syndrome? |
| Q45867702 | Standardization of lupus anticoagulant. Feasibility study of a calibration model to minimize between-method variability |
| Q45879352 | Standardization of lupus anticoagulant. The Lupus Anticoagulant Sensitivity Index (LASI). |
| Q80223750 | Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples |
| Q89691164 | Tetra positive thrombotic antiphospholipid syndrome: Major contribution of anti-phosphatidyl-serine/prothrombin antibodies to lupus anticoagulant activity |
| Q91649772 | The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases |
| Q28547424 | The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation |
| Q84438431 | The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study |
| Q38703934 | The challenges of lupus anticoagulants |
| Q64041096 | The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis |
| Q36541475 | The diagnosis of the antiphospholipid syndrome |
| Q51127291 | The long-term risk of cancer in patients with a first episode of venous thromboembolism. |
| Q51182390 | The negative predictive value of D-dimer on the risk of recurrent venous thromboembolism in patients with multiple previous events: a prospective cohort study (the PROLONG PLUS study). |
| Q48060132 | The paradox of the lupus anticoagulant: history and perspectives. |
| Q34082896 | The redox enzyme p66Shc contributes to diabetes and ischemia-induced delay in cutaneous wound healing. |
| Q82867004 | The risk of cancer in patients with venous thromboembolism does not exceed that expected in the general population after the first 6 months |
| Q79765195 | The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients |
| Q81446001 | Thrombophilia in young patients with cryptogenic stroke and patent foramen ovale (PFO) |
| Q41036908 | To treat or not to treat very elderly naïve patients with atrial fibrillation with vitamin K antagonists (VKA): results from the VENPAF cohort. |
| Q101134129 | Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure |
| Q93047783 | Triple Antiphospholipid (aPL) Antibodies Positivity Is Associated With Pregnancy Complications in aPL Carriers: A Multicenter Study on 62 Pregnancies |
| Q53190445 | Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. |
| Q51767834 | Use of D-dimer testing to determine duration of anticoagulation, risk of cardiovascular events and occult cancer after a first episode of idiopathic venous thromboembolism: the extended follow-up of the PROLONG study. |
| Q53260251 | Use of a new silica clotting time for diagnosing lupus anticoagulant in patients who meet the clinical criteria for antiphospholipid syndrome. |
| Q98938286 | Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis |
| Q56989286 | Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study |
| Q51622508 | VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study. |
| Q34949493 | Variability in exposure of epitope G40-R43 of domain i in commercial anti-beta2-glycoprotein I IgG ELISAs |
| Q57300702 | Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis |
| Q38787469 | Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20 years ago. |
| Q45873657 | Warfarin prescription in patients with nonvalvular atrial fibrillation and one non-gender-related risk factor (CHA2 DS2 VASc 1 or 2): A treatment dilemma |
| Q37991555 | What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts? |
| Q82538486 | Worldwide management of oral anticoagulant therapy: the ISAM study |
| Q51074186 | β2 -Glycoprotein I binds to thrombin and selectively inhibits the enzyme procoagulant functions. |
| Q28218556 | Low-intensity oral anticoagulant plus low-dose aspirin during the first six months versus standard-intensity oral anticoagulant therapy after mechanical heart valve replacement: a pilot study of low-intensity warfarin and aspirin in cardiac prosthes |
Search more.